-
Mashup Score: 9
Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following concurrent chemoradiotherapy (cCRT) compared to placebo after cCRT. Small cell lung cancer (SCLC) is a highly aggressive form of lung
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 6
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease. The Prescription Drug User Fee Act date, the US Food and Drug Administration (FDA) action date for its regulatory decision, is during
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 2TIME logo - 1 month(s) ago
This is paid content on behalf of our sponsor. TIME editorial staff was not involved in its creation or production.
Source: partners.time.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3
Latest analysis of the results from the DUO-E Phase III trial showed IMFINZI ® (durvalumab) plus platinum-based chemotherapy followed by IMFINZI plus LYNPARZA ® (olaparib) (LYNPARZA and IMFINZI arm) demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared to chemotherapy alone. These results will be presented today in a late-breaking session at the 2024 Society of Gynecologic
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 5Understanding ATTR: The Challenges of Amyloidosis - 2 month(s) ago
Transthyretin amyloidosis (ATTR) is a complex medical condition that happens when a protein called transthyretin (TTR) does something different than what it’s supposed to do in the body. Normally, TTR is a four-piece protein produced mostly in the liver that helps carry important substances, like thyroxine (thyroid hormones) and vitamin A, throughout the body. When someone has ATTR, the pieces of TTR fall apart, misfold, and change shape. These pieces bind together to form larger structures called
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3National Kidney Month – Speaking with Your Doctor about CKD - 2 month(s) ago
March is National Kidney Month—a time to raise awareness about the importance of kidney health. Chronic Kidney Disease (CKD) affects an estimated 37 million Americans, and it is often referred to as a “silent disease” because there are usually no symptoms during its early stages. In fact, as many as 90% of Americans who have chronic kidney disease (CKD) don’t know they have it until it is very advanced. The kidneys play an important role in helping our bodies function properly. When the kidneys are
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet-
#DidYouKnow that early detection is key to slowing the progression of chronic kidney disease (CKD)? This #NationalKidneyMonth and #WorldKidneyDay, speak to your doctor about #CKD risk factors and develop a management plan that’s right for you. Learn more: https://t.co/Yxo3Z5UeJA https://t.co/9Xoh68AVyj
-
-
Mashup Score: 0National Kidney Month – Speaking with Your Doctor about CKD - 2 month(s) ago
March is National Kidney Month—a time to raise awareness about the importance of kidney health. Chronic Kidney Disease (CKD) affects an estimated 37 million Americans, and it is often referred to as a “silent disease” because there are usually no symptoms during its early stages. In fact, as many as 90% of Americans who have chronic kidney disease (CKD) don’t know they have it until it is very advanced. The kidneys play an important role in helping our bodies function properly. When the kidneys are
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet-
It’s #NationalKidneyMonth. Did you know that earlier detection of #ChronicKidneyDisease (CKD) can improve patient outcomes, limiting the impact on health systems, caregivers, economies and the environment? Learn more about #CKD management and our promise: https://t.co/hgHUNfOgHm https://t.co/VLjPy9yaj1
-
-
Mashup Score: 0That's Understandable - 2 month(s) ago
You are now leaving AstraZeneca-us.com You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. Important notice for users You are about to access
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 4
If approved, AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan may be the first TROP2-directed antibody drug conjugate for patients with lung cancer AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy. The Prescription Drug User Fee Act date, the Food and Drug
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet-
In collaboration with @DaiichiSankyoUS, we announced the @US_FDA has accepted a Biologics License Application for our potential treatment for adult patients with previously treated advanced or metastatic nonsquamous non-small cell #lungcancer #NSCLC https://t.co/SPdMyRG4cb #AZUS https://t.co/RHqF5NmzAt
-
-
Mashup Score: 39
Positive high-level results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO ® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) compared to placebo after CRT. Overall survival (OS) data showed a favorable trend for TAGRISSO, although data were not mature
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
Today, we announced positive high-level results from the ADRIATIC Phase III trial in patients with limited-stage small cell #lungcancer. Learn more: https://t.co/hBxKif24yB #AZUS https://t.co/ZgNp5hKJ2q